Activates GLP-1 receptors, favoring cAMP signaling while reducing recruitment of beta-arrestin. Oral and injectable formulations contain the same receptor-active compound.
Chinese injection approved for adult type 2 diabetes in January 2026 and chronic weight management in March 2026; Pfizer China is the exclusive Mainland-China commercialization partner. Oral XW004 remains investigational.
13.2% reported weight loss · 0.1% gain with placebo · 40 weeks
2.4 mg once weekly
Chinese adults with overweight or obesity without diabetes
Primary endpoint at week 40; full analysis set includes randomized participants receiving >=1 dose. Chinese injection approved for adult type 2 diabetes in January 2026 and chronic weight management in March 2026; Pfizer China is the exclusive Mainland-China commercialization partner. Oral XW004 remains investigational.
Safety context
GI events predominated; 10 participants across all ecnoglutide arms stopped for adverse events.
Limitations: Trial continued to week 48; robustly verified primary treatment-policy endpoint is week 40. Week 48 headline 15.4% belongs to a different analysis and must not silently replace this.
6.8% reported weight loss · 0.9% loss with placebo · 6 weeks
30 mg daily
14 otherwise healthy Australian adults with obesity in cohort4; trial also included42 healthy participants
Not specified in public report Oral weekly formulation phase 1b/2a commenced November 2025; next readout expected the first half of 2027 per March 2026 filing.
Safety context
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: Tiny six-week daily-formulation cohort; does not establish efficacy of newer once-weekly oral formulation.
Chinese adults aged 18–75 with type 2 diabetes; BMI 20–35 kg/m²
Full analysis set; MMRM treatment-policy estimate regardless of discontinuation or rescue therapy.
Safety context
GI events were common. One participant per group discontinued because of an adverse event; no severe hypoglycemia reported.
Limitations: Initial 24-week randomized comparison only; placebo participants switched to ecnoglutide afterward. Prior oral-drug use was permitted at screening.
Status in this atlas: Chinese injection approved for adult type 2 diabetes in January 2026 and chronic weight management in March 2026; Pfizer China is the exclusive Mainland-China commercialization partner. Oral XW004 remains investigational. Status source
Activates GLP-1 receptors, favoring cAMP signaling while reducing recruitment of beta-arrestin. Oral and injectable formulations contain the same receptor-active compound.
Name in Sciwind's January 2026 Chinese approval announcement for injectable treatment of adult type 2 diabetes. · injection
Sciwind Biosciences · Originator; Chinese marketing-authorization holder responsible for development, registration, manufacture and supply.; Pfizer China · Exclusive Mainland-China commercialization partner for injectable ecnoglutide.; Verdiva Bio · Oral ecnoglutide/XW004 development and commercialization licensee outside Greater China and South Korea.; HK inno.N · Development and commercialization partner for injectable ecnoglutide in South Korea.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates GLP-1 receptors, favoring cAMP signaling while reducing recruitment of beta-arrestin. Oral and injectable formulations contain the same receptor-active compound.
Structure not yet verified
Structure not verified
Activates GLP-1 receptors, favoring cAMP signaling while reducing recruitment of beta-arrestin. Oral and injectable formulations contain the same receptor-active compound.
Shown: Peptide drug
A named PubChem record was found, but the complete peptide modifications and stereochemistry were not independently reconciled during this review; no exact-drug image is presented.